Literature DB >> 8146663

Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels.

R Etcheberrigaray1, E Ito, C S Kim, D L Alkon.   

Abstract

Although beta-amyloid is the main constituent of neurite plaques and may play a role in the pathophysiology of Alzheimer's disease, mechanisms by which soluble beta-amyloid might produce early symptoms such as memory loss before diffuse plaque deposition have not been implicated. Treatment of fibroblasts with beta-amyloid (10 nM) induced the same potassium channel dysfunction previously shown to occur specifically in fibroblasts from patients with Alzheimer's disease--namely, the absence of a 113-picosiemen potassium channel. A tetraethylammonium-induced increase of intracellular concentrations of calcium, [Ca2+]i, a response that depends on functional 113-picosiemen potassium channels, was also eliminated or markedly reduced by 10 nM beta-amyloid. Increased [Ca2+]i induced by high concentrations of extracellular potassium and 166-picosiemen potassium channels were unaffected by 10 nM beta-amyloid. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8146663     DOI: 10.1126/science.8146663

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  22 in total

1.  Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

Authors:  J F Kelly; K Furukawa; S W Barger; M R Rengen; R J Mark; E M Blanc; G S Roth; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Amyloid ion channels: a common structural link for protein-misfolding disease.

Authors:  Arjan Quist; Ivo Doudevski; Hai Lin; Rushana Azimova; Douglas Ng; Blas Frangione; Bruce Kagan; Jorge Ghiso; Ratnesh Lal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-14       Impact factor: 11.205

3.  Beta-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons.

Authors:  T A Good; D O Smith; R M Murphy
Journal:  Biophys J       Date:  1996-01       Impact factor: 4.033

Review 4.  Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity.

Authors:  H B Pollard; N Arispe; E Rojas
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

5.  Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts.

Authors:  A Favit; M Grimaldi; T J Nelson; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 6.  Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease.

Authors:  R J Mark; E M Blanc; M P Mattson
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

Review 7.  Alzheimer's disease and prion proteins: a meeting made in muscle.

Authors:  P Gambetti; G Perry
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors:  Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal:  Neurobiol Dis       Date:  2009-02-20       Impact factor: 5.996

9.  Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20.

Authors:  C S Kim; Y F Han; R Etcheberrigaray; T J Nelson; J L Olds; T Yoshioka; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.

Authors:  René Etcheberrigaray; Mathew Tan; Ilse Dewachter; Cuno Kuipéri; Ingrid Van der Auwera; Stefaan Wera; Lixin Qiao; Barry Bank; Thomas J Nelson; Alan P Kozikowski; Fred Van Leuven; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.